Literature DB >> 32504837

Opioid system influences gut-brain axis: Dysbiosis and related alterations.

Lola Rueda-Ruzafa1, Francisco Cruz2, Diana Cardona3, Arik J Hone4, Guadalupe Molina-Torres5, Nuria Sánchez-Labraca6, Pablo Roman7.   

Abstract

Opioid drugs are widely used to treat chronic pain, but their misuse can lead to tolerance, dependence, and addiction and have created a significant public health problem. In addition, food-derived opioid peptides, known as exorphins, like gluten exorphins have been shown to have harmful effects in certain pathologies like celiac disease, for example. Several studies support the involvement of the opioid system in the development of disorders such as autism spectrum syndrome. Moreover, bidirectional communication between the intestine and brain has been shown to be altered in various neurodegenerative diseases including Alzheimer´s and Parkinson´s. The presence of opioid receptors in both the digestive tract and the central nervous system (CNS) suggests that opioid drugs and exorphins may modulate the gut-brain axis. Morphine, for example, has shown a dysbiotic effect on the bacterial microbiota in addition to inducing an increase in intestinal permeability facilitating bacterial translocation. Furthermore, certain components of bacteria can modify the expression of opioid receptors at the central level increasing sensitivity to pain. Strategies based on use of probiotics have resulted in improvements in symptoms of autism and Parkinson´s disease. In this manuscript, we review the role of the opioid system in disorders and CNS pathologies and the involvement of the gut-brain axis.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Casomorphin; Gluten probiotics; Gut microbiota; Gut-brain axis; Morphine; Opioid

Mesh:

Substances:

Year:  2020        PMID: 32504837     DOI: 10.1016/j.phrs.2020.104928

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  7 in total

Review 1.  The placenta as a target of opioid drugs†.

Authors:  Cheryl S Rosenfeld
Journal:  Biol Reprod       Date:  2022-04-26       Impact factor: 4.161

2.  Gut microbiota plays a pivotal role in opioid-induced adverse effects in gastrointestinal system.

Authors:  Rongpeng Xu; Liying Miao; Chun Yang; Bin Zhu
Journal:  Crit Care       Date:  2022-01-03       Impact factor: 9.097

Review 3.  The Current View on the Paradox of Pain in Autism Spectrum Disorders.

Authors:  Olena V Bogdanova; Volodymyr B Bogdanov; Adrien Pizano; Manuel Bouvard; Jean-Rene Cazalets; Nicholas Mellen; Anouck Amestoy
Journal:  Front Psychiatry       Date:  2022-07-22       Impact factor: 5.435

4.  Food-Specific IgG4 Antibody-Guided Exclusion Diet Improves Conditions of Patients with Chronic Pain.

Authors:  Ilenia Casini; Elena Fatighenti; Antonella Giannantoni; Lauretta Massai; Stefano Pieretti; Ilaria Ceccarelli; Anna Maria Aloisi
Journal:  Pain Ther       Date:  2022-05-25

Review 5.  Sex-dependent impact of microbiota status on cerebral μ-opioid receptor density in fischer rats.

Authors:  Felix Effah; Nívea Karla de Gusmão Taveiros Silva; Katie Vijayanathan; Rosana Camarini; Fatima Joly; Benjamin Taiwo; Sylvie Rabot; Gaëlle Champeil-Potokar; Vincent Bombail; Alexis Bailey
Journal:  Eur J Neurosci       Date:  2022-04-24       Impact factor: 3.698

Review 6.  Pain and Opioid-Induced Gut Microbial Dysbiosis.

Authors:  Karen R Thomas; Jacob Watt; Chuen Mong J Wu; Adejoke Akinrinoye; Sairah Amjad; Lucy Colvin; Rachel Cowe; Sylvia H Duncan; Wendy R Russell; Patrice Forget
Journal:  Biomedicines       Date:  2022-07-28

Review 7.  The Role of Dysbiosis in Critically Ill Patients With COVID-19 and Acute Respiratory Distress Syndrome.

Authors:  Denise Battaglini; Chiara Robba; Andrea Fedele; Sebastian Trancǎ; Samir Giuseppe Sukkar; Vincenzo Di Pilato; Matteo Bassetti; Daniele Roberto Giacobbe; Antonio Vena; Nicolò Patroniti; Lorenzo Ball; Iole Brunetti; Antoni Torres Martí; Patricia Rieken Macedo Rocco; Paolo Pelosi
Journal:  Front Med (Lausanne)       Date:  2021-06-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.